USP5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL774547	0.39	8/20
SCHEMBL832746	0.52	7/20
SCHEMBL1222675	0.55	5/20
SCHEMBL2420683	0.43	4/20
SCHEMBL2422850	0.42	4/20
SCHEMBL2422935	0.58	3/20
SCHEMBL941270	0.49	3/20
SCHEMBL1312750	0.49	3/20
Hippuric Acid (SCHEMBL3029)	0.48	3/20
Hippuric Acid (SCHEMBL2405067)	0.48	3/20
Hippuric Acid (SCHEMBL2464569)	0.45	3/20
SCHEMBL2420008	0.43	3/20
SCHEMBL425024	0.43	3/20
SCHEMBL2422704	0.42	3/20
SCHEMBL2422524	0.41	3/20
Bucloxic Acid (SCHEMBL25652)	0.41	3/20
SCHEMBL2420939	0.41	3/20
SCHEMBL2426626	0.41	3/20
SCHEMBL363414	0.37	3/20
SCHEMBL1390981	0.37	3/20

Clinical trials — most relevant to USP5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study	PHASE3	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma	nan	COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	nan	UNKNOWN
Inherited Reproductive Disorders	nan	RECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a USP5 binder may also engage these)

Protein	Name	Similarity
Q5R407	—	1.000	Q5R407 →
P56399	—	1.000	P56399 →
E1BMF7	—	0.987	E1BMF7 →
USP13	Ubiquitin carboxyl-terminal hydrolase 13	0.983	landscape →
Q5BKP2	—	0.982	Q5BKP2 →
F1QFS9	—	0.981	F1QFS9 →
E1BY77	—	0.981	E1BY77 →
Q84WC6	—	0.974	Q84WC6 →
Q4VSI4	—	0.973	Q4VSI4 →
USP7	Ubiquitin carboxyl-terminal hydrolase 7	0.972	landscape →
F6V6I0	—	0.971	F6V6I0 →
Q6U7I1	—	0.971	Q6U7I1 →
Q6A4J8	—	0.970	Q6A4J8 →
P40826	—	0.969	P40826 →
Q949Y0	—	0.969	Q949Y0 →
Q8L6Y1	—	0.968	Q8L6Y1 →
Q5ZJX5	—	0.968	Q5ZJX5 →
Q32Q05	—	0.967	Q32Q05 →
Q07139	—	0.967	Q07139 →
Q9JMA1	—	0.967	Q9JMA1 →
Q9UNN5	—	0.967	Q9UNN5 →
Q0IIF7	—	0.967	Q0IIF7 →
Q92353	—	0.967	Q92353 →
P60670	—	0.967	P60670 →
Q6NX27	—	0.966	Q6NX27 →
Q9VUV9	—	0.966	Q9VUV9 →
USP14	Ubiquitin carboxyl-terminal hydrolase 14	0.966	landscape →
Q6GM65	—	0.966	Q6GM65 →
Q8N1G2	—	0.966	Q8N1G2 →
Q5R981	—	0.966	Q5R981 →